FDA rejects Teva’s high-potency biosimilar of Humira again

FDA rejects Teva’s high-potency biosimilar of Humira again

Submitted by admin on April 14, 2023 - 10:37am
Source: 
Pharmaphorum
News Tags: 
Teva Pharmaceutical
Alvotech
biosimilars
FDA
Humira
Headline: 
FDA rejects Teva’s high-potency biosimilar of Humira again
snippet: 

Teva and partner Alvotech’s hopes of launching their biosimilar of AbbVie’s high-potency formulation of big-selling immunology drug Humira have been dashed, after the FDA turned down their marketing application for the second time.

Do Not Allow Advertisers to Use My Personal information